ArticleBMC nephrology2023
Machine learning models to predict end-stage kidney disease in chronic kidney disease stage 4.
Article in BMC nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Applications of artificial intelligence in chronic kidney disease: a systematic review.Revista de saude publica · 2026Pooled it
- Development and external validation of an explainable machine learning model for predicting chronic kidney disease progression in the Korean population.Kidney research and clinical practice · 2026Article
- Predicting End-Stage Renal Disease and Mortality in Chronic Kidney Disease Using Machine Learning: Retrospective Cohort Study.JMIR medical informatics · 2026Article
- Interpretable bioimpedance-based modeling of body composition and metabolic indices related to physical function in maintenance hemodialysis patients.Frontiers in nutrition · 2026Article
- Stacking ensemble model for predicting chronic kidney disease in the Uddanam region of India with unknown etiology.Scientific reports · 2025Article
- Machine learning models for predicting short-term progression in patients with stage 4 chronic kidney disease: a multi-center validation study.Scientific reports · 2025Observational
- Associations between parental protective motivation, behaviors, and child outcomes in allergic diseases: a cross-sectional study based on protection motivation theory.BMC public health · 2025Article
- Artificial Intelligence in Nephrology: From Early Detection to Clinical Management of Kidney Diseases.Bioengineering (Basel, Switzerland) · 2025Review
- Applicability Assessment of Technologies for Predictive and Prescriptive Analytics of Nephrology Big Data.Proteomics · 2025Review
- A Tutorial and Use Case Example of the eXtreme Gradient Boosting (XGBoost) Artificial Intelligence Algorithm for Drug Development Applications.Clinical and translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
introductionEnd-stage kidney disease (ESKD) is associated with increased morbidity and mortality. Identifying patients with stage 4 CKD (CKD4) at risk of rapid progression to ESKD remains challenging. Accurate prediction of CKD4 progression can improve patient outcomes by improving advanced care planning and optimizing healthcare resource allocation.
methodsWe obtained electronic health record data from patients with CKD4 in a large health system between January 1, 2006, and December 31, 2016. We developed and validated four models, including Least Absolute Shrinkage and Selection Operator (LASSO) regression, random forest, eXtreme Gradient Boosting (XGBoost), and artificial neural network (ANN), to predict ESKD at 3 years. We utilized area under the receiver operating characteristic curve (AUROC) to evaluate model performances and utilized Shapley additive explanation (SHAP) values and plots to define feature dependence of the best performance model.
resultsWe included 3,160 patients with CKD4. ESKD was observed in 538 patients (21%). All approaches had similar AUROCs; ANN yielded the highest AUROC (0.77; 95%CI 0.75 to 0.79) and LASSO regression (0.77; 95%CI 0.75 to 0.79), followed by random forest (0.76; 95% CI 0.74 to 0.79), and XGBoost (0.76; 95% CI 0.74 to 0.78).
conclusionsWe developed and validated several models for near-term prediction of kidney failure in CKD4. ANN, random forest, and XGBoost demonstrated similar predictive performances. Using this suite of models, interventions can be customized based on risk, and population health and resources appropriately allocated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.